2025 Q3 -tulosraportti
37 päivää sitten46 min
Tarjoustasot
Oslo Børs
Määrä
Osto
240
Myynti
Määrä
184
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 194 | - | - | ||
| 316 | - | - | ||
| 816 | - | - | ||
| 230 | - | - | ||
| 22 | - | - |
Ylin
64,5VWAP
Alin
63,6VaihtoMäärä
2 31 407
VWAP
Ylin
64,5Alin
63,6VaihtoMäärä
2 31 407
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 29.10. | |
| 2025 Q2 -tulosraportti | 30.7. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 19.2. | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sitten · MuokattuNow we are approximately at the point where 50-60 traders have typically dumped many shares for sale to drive it down again to the rinse and repeat level. But is it perhaps becoming less and less comfortable to take that trade? Time will tell.
·23 t sittenYes, it looks very promising now on all parameters.
·2 päivää sitten- ·27.11.Excerpt from Tekinvestor Investor Day 27 Nov 2025 Summary: Status of APL-1702 and the process in CDE "APL-1702 NDA advances to the second round of technical review." "The review pause is a normal part of the process." "The pause does not require the submission of new supplementary documents." "The company will maintain proactive communication with the Center for Drug Evaluation (CDE) to expedite the New Drug Application (NDA) review process." "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform." Political framework in China "To advance the Healthy China 2030 initiative… the Chinese government has issued key policies, including the Healthy China Initiative: Implementation Plan for Cancer Prevention and Control and the Action Plan for Accelerating Elimination of Cervical Cancer (2023–2030)." "The National Health Commission revealed that the risk of cervical cancer is rising in China, particularly among younger women." "There is still much to be done in the fight to control and prevent this disease." Clinical and social significance of APL-1702 "APL-1702 is a groundbreaking product that combines innovative, clinical, and social value." "It is poised to become the world’s first non-invasive therapy for HSIL." "Clinically, APL-1702 is set to redefine the treatment paradigm of precancerous cervical lesions, moving beyond the one-size-fits-all approach of cervical resection." "It aims to reverse disease progression while preserving the cervix, avoiding damage from resection, and supporting long-term management and recurrence prevention." "APL-1702 combines the value of early cervical cancer intervention and the promotion of a fertility-friendly society." "APL-1702… backed by proven efficacy in an international phase III trial… is expected to contribute to the success of the Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030) and the Healthy China Initiative." Platform and portfolio strategy "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform, in a bid to build a comprehensive, tiered gynecological portfolio." "This strategy will center on product iteration and indication expansion, while leveraging synergies across the pipeline to drive broader growth." APL-1706 (Hexvix) / Richard Wolf "Asieris supports Richard Wolf in its efforts to obtain marketing approval for SYSTEM BLUE in China." "SYSTEM BLUE is in the marketing review/approval stage." "APL-1706 continues to be part of the company’s focus areas."
·2 päivää sittenI believe you underestimate both today's challenges and the market potential. Surgery (LEEP/conization) is effective, but it is not “100 %” and not without risk – especially for young women who wish to have children. Several large studies show an increased risk of premature birth after conization, and a significant proportion of CIN2 regresses spontaneously. Therefore, there is a real clinical need for a fertility-preserving alternative. In phase III, APL-1702 showed clearly better efficacy than placebo (41 % response vs 22 %, and approximately twice as high HPV clearance), with mainly mild side effects. This makes it the first documented, non-surgical treatment for HSIL. Surgery will still be important, but in a country where millions of women get HSIL every year, it is unrealistic to call this a “small patient group”. Even moderate adoption can yield significant volume.·2 päivää sittenWould not attribute much value to investinor's considerations. Only looking to talk down. 
·26.11.Put on the diving goggles again? Paused in the queue again
·26.11.In the only remaining one for «pharmacy»? In that case, it's something you can probably take with absolute calm.
·26.11.Oh? There are probably plenty of examples earlier on the list, which gives a good indication that this review can also become time-consuming 😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
37 päivää sitten46 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten · MuokattuNow we are approximately at the point where 50-60 traders have typically dumped many shares for sale to drive it down again to the rinse and repeat level. But is it perhaps becoming less and less comfortable to take that trade? Time will tell.·23 t sittenYes, it looks very promising now on all parameters.
- ·2 päivää sitten
- ·27.11.Excerpt from Tekinvestor Investor Day 27 Nov 2025 Summary: Status of APL-1702 and the process in CDE "APL-1702 NDA advances to the second round of technical review." "The review pause is a normal part of the process." "The pause does not require the submission of new supplementary documents." "The company will maintain proactive communication with the Center for Drug Evaluation (CDE) to expedite the New Drug Application (NDA) review process." "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform." Political framework in China "To advance the Healthy China 2030 initiative… the Chinese government has issued key policies, including the Healthy China Initiative: Implementation Plan for Cancer Prevention and Control and the Action Plan for Accelerating Elimination of Cervical Cancer (2023–2030)." "The National Health Commission revealed that the risk of cervical cancer is rising in China, particularly among younger women." "There is still much to be done in the fight to control and prevent this disease." Clinical and social significance of APL-1702 "APL-1702 is a groundbreaking product that combines innovative, clinical, and social value." "It is poised to become the world’s first non-invasive therapy for HSIL." "Clinically, APL-1702 is set to redefine the treatment paradigm of precancerous cervical lesions, moving beyond the one-size-fits-all approach of cervical resection." "It aims to reverse disease progression while preserving the cervix, avoiding damage from resection, and supporting long-term management and recurrence prevention." "APL-1702 combines the value of early cervical cancer intervention and the promotion of a fertility-friendly society." "APL-1702… backed by proven efficacy in an international phase III trial… is expected to contribute to the success of the Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030) and the Healthy China Initiative." Platform and portfolio strategy "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform, in a bid to build a comprehensive, tiered gynecological portfolio." "This strategy will center on product iteration and indication expansion, while leveraging synergies across the pipeline to drive broader growth." APL-1706 (Hexvix) / Richard Wolf "Asieris supports Richard Wolf in its efforts to obtain marketing approval for SYSTEM BLUE in China." "SYSTEM BLUE is in the marketing review/approval stage." "APL-1706 continues to be part of the company’s focus areas."·2 päivää sittenI believe you underestimate both today's challenges and the market potential. Surgery (LEEP/conization) is effective, but it is not “100 %” and not without risk – especially for young women who wish to have children. Several large studies show an increased risk of premature birth after conization, and a significant proportion of CIN2 regresses spontaneously. Therefore, there is a real clinical need for a fertility-preserving alternative. In phase III, APL-1702 showed clearly better efficacy than placebo (41 % response vs 22 %, and approximately twice as high HPV clearance), with mainly mild side effects. This makes it the first documented, non-surgical treatment for HSIL. Surgery will still be important, but in a country where millions of women get HSIL every year, it is unrealistic to call this a “small patient group”. Even moderate adoption can yield significant volume.·2 päivää sittenWould not attribute much value to investinor's considerations. Only looking to talk down.
- ·26.11.Put on the diving goggles again? Paused in the queue again·26.11.In the only remaining one for «pharmacy»? In that case, it's something you can probably take with absolute calm.·26.11.Oh? There are probably plenty of examples earlier on the list, which gives a good indication that this review can also become time-consuming 😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
240
Myynti
Määrä
184
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 194 | - | - | ||
| 316 | - | - | ||
| 816 | - | - | ||
| 230 | - | - | ||
| 22 | - | - |
Ylin
64,5VWAP
Alin
63,6VaihtoMäärä
2 31 407
VWAP
Ylin
64,5Alin
63,6VaihtoMäärä
2 31 407
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 29.10. | |
| 2025 Q2 -tulosraportti | 30.7. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 19.2. | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
37 päivää sitten46 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 29.10. | |
| 2025 Q2 -tulosraportti | 30.7. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 19.2. | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten · MuokattuNow we are approximately at the point where 50-60 traders have typically dumped many shares for sale to drive it down again to the rinse and repeat level. But is it perhaps becoming less and less comfortable to take that trade? Time will tell.·23 t sittenYes, it looks very promising now on all parameters.
- ·2 päivää sitten
- ·27.11.Excerpt from Tekinvestor Investor Day 27 Nov 2025 Summary: Status of APL-1702 and the process in CDE "APL-1702 NDA advances to the second round of technical review." "The review pause is a normal part of the process." "The pause does not require the submission of new supplementary documents." "The company will maintain proactive communication with the Center for Drug Evaluation (CDE) to expedite the New Drug Application (NDA) review process." "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform." Political framework in China "To advance the Healthy China 2030 initiative… the Chinese government has issued key policies, including the Healthy China Initiative: Implementation Plan for Cancer Prevention and Control and the Action Plan for Accelerating Elimination of Cervical Cancer (2023–2030)." "The National Health Commission revealed that the risk of cervical cancer is rising in China, particularly among younger women." "There is still much to be done in the fight to control and prevent this disease." Clinical and social significance of APL-1702 "APL-1702 is a groundbreaking product that combines innovative, clinical, and social value." "It is poised to become the world’s first non-invasive therapy for HSIL." "Clinically, APL-1702 is set to redefine the treatment paradigm of precancerous cervical lesions, moving beyond the one-size-fits-all approach of cervical resection." "It aims to reverse disease progression while preserving the cervix, avoiding damage from resection, and supporting long-term management and recurrence prevention." "APL-1702 combines the value of early cervical cancer intervention and the promotion of a fertility-friendly society." "APL-1702… backed by proven efficacy in an international phase III trial… is expected to contribute to the success of the Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030) and the Healthy China Initiative." Platform and portfolio strategy "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform, in a bid to build a comprehensive, tiered gynecological portfolio." "This strategy will center on product iteration and indication expansion, while leveraging synergies across the pipeline to drive broader growth." APL-1706 (Hexvix) / Richard Wolf "Asieris supports Richard Wolf in its efforts to obtain marketing approval for SYSTEM BLUE in China." "SYSTEM BLUE is in the marketing review/approval stage." "APL-1706 continues to be part of the company’s focus areas."·2 päivää sittenI believe you underestimate both today's challenges and the market potential. Surgery (LEEP/conization) is effective, but it is not “100 %” and not without risk – especially for young women who wish to have children. Several large studies show an increased risk of premature birth after conization, and a significant proportion of CIN2 regresses spontaneously. Therefore, there is a real clinical need for a fertility-preserving alternative. In phase III, APL-1702 showed clearly better efficacy than placebo (41 % response vs 22 %, and approximately twice as high HPV clearance), with mainly mild side effects. This makes it the first documented, non-surgical treatment for HSIL. Surgery will still be important, but in a country where millions of women get HSIL every year, it is unrealistic to call this a “small patient group”. Even moderate adoption can yield significant volume.·2 päivää sittenWould not attribute much value to investinor's considerations. Only looking to talk down.
- ·26.11.Put on the diving goggles again? Paused in the queue again·26.11.In the only remaining one for «pharmacy»? In that case, it's something you can probably take with absolute calm.·26.11.Oh? There are probably plenty of examples earlier on the list, which gives a good indication that this review can also become time-consuming 😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
240
Myynti
Määrä
184
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 194 | - | - | ||
| 316 | - | - | ||
| 816 | - | - | ||
| 230 | - | - | ||
| 22 | - | - |
Ylin
64,5VWAP
Alin
63,6VaihtoMäärä
2 31 407
VWAP
Ylin
64,5Alin
63,6VaihtoMäärä
2 31 407
Välittäjätilasto
Dataa ei löytynyt